AMR101 (ethyl icosapentate) - 2 g/day

DRUG2 trials

Sponsors

Amarin Pharma Inc.

Conditions

Hypertriglyceridemia

Phase 3

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

CompletedNCT01047683

Amarin Pharma Inc.Hypertriglyceridemia

Start: 2009-12-31End: 2011-07-31Updated: 2022-04-25

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

CompletedNCT01047501

Amarin Pharma Inc.Hypertriglyceridemia

Start: 2009-12-31End: 2011-02-28Updated: 2022-04-25

Related Papers

Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis.

2020-11-181 citations

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.

2019-02-2016 citations

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.

2013-07-0957 citations

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

2012-07-2468 citations